Latest Earnings Results: Q3 '26
Estimated EPS
-$0.07
Reported EPS
-$0.05
Surprise
+26.47%
Estimated Rev
$136.62M
Reported Rev
$65.4M
Surprise
-52.13%
• Reported GAAP EPS of -$0.07 down -333.33% YoY • Reported revenue of $65.4M down -56.88% YoY
Bullish Takeaway
OPKO Health's Global Products segment returned to operating income as revenue rose; Regeneron collaboration offers potential milestone payments, while the Labcorp agreement includes $722M cash consideration plus contingent 4Kscore proceeds.
Bearish Takeaway
OPKO Health continued operating cash outflows and reports no history of sustained positive cash flow; Innovative Biotech losses widened amid higher development spending; BioReference liabilities remain after sale, pending approvals.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.07 | -- | -- | N/A |
Q3 '26 | -$0.07 | -$0.05 | 26.47% | BEAT |
Q2 '26 | -$0.08 | -$0.01 | 87.50% | BEAT |
Q1 '26 | -$0.07 | -$0.07 | -- | EXPECTED |
Q4 '25 | -$0.07 | -$0.04 | 41.67% | BEAT |